Science News
from research organizations

Revolutionary eye drops to treat age-related blindness

Date:
May 15, 2017
Source:
University of Birmingham
Summary:
A type of eye drop has been developed that could potentially revolutionize the treatment of one of the leading causes of blindness, age-related macular degeneration.
Share:
FULL STORY

Scientists at the University of Birmingham have developed a type of eye drop which could potentially revolutionize the treatment of one of the leading causes of blindness in the UK.

The results of the collaborative research, published in Investigative Opthamology and Visual Science, could spell the end of painful injections directly into the eye to treat the increasingly common eye disorder known as age-related macular degeneration (AMD).

AMD affects more than 600,000 people in the UK and predictions suggest this figure could rise sharply in future because of an aging population.

A painless condition which causes people to gradually lose their central vision, usually in both eyes, AMD is currently treated by repeated injections into the eye on a monthly basis over at least three years.

This is a problem because, apart from being an unpleasant procedure for patients to undergo, the injections can cause tearing and infections inside the eye and an increased risk of blindness.

Now scientists led by biochemist Dr Felicity de Cogan, from the University of Birmingham's Institute of Inflammation and Ageing, have invented a method of delivering the injected drug as an eye drop instead, and their laboratory research has obtained the same outcomes as the injected drug.

The drop uses a cell-penetrating peptide (CPP) to deliver the drug to the relevant part of the eye within minutes.

Dr de Cogan said: "The CPP-drug has the potential to have a significant impact on the treatment of AMD by revolutionising drug-delivery options.

"Efficacious self-administered drug application by eye drop would lead to a significant reduction in adverse outcomes and health care costs compared with current treatments.

"The CPP-plus drug complex also has potential application to other chronic ocular diseases that require drug delivery to the posterior chamber of the eye.

"We believe this is going to be very important in terms of empowering of patients and reducing the cost of treatment to the NHS."


Story Source:

Materials provided by University of Birmingham. Note: Content may be edited for style and length.


Journal Reference:

  1. Felicity de Cogan, Lisa J. Hill, Aisling Lynch, Peter J. Morgan-Warren, Judith Lechner, Matthew R. Berwick, Anna F. A. Peacock, Mei Chen, Robert A. H. Scott, Heping Xu, Ann Logan. Topical Delivery of Anti-VEGF Drugs to the Ocular Posterior Segment Using Cell-Penetrating Peptides. Investigative Opthalmology & Visual Science, 2017; 58 (5): 2578 DOI: 10.1167/iovs.16-20072

Cite This Page:

University of Birmingham. "Revolutionary eye drops to treat age-related blindness." ScienceDaily. ScienceDaily, 15 May 2017. <www.sciencedaily.com/releases/2017/05/170515122207.htm>.
University of Birmingham. (2017, May 15). Revolutionary eye drops to treat age-related blindness. ScienceDaily. Retrieved May 22, 2017 from www.sciencedaily.com/releases/2017/05/170515122207.htm
University of Birmingham. "Revolutionary eye drops to treat age-related blindness." ScienceDaily. www.sciencedaily.com/releases/2017/05/170515122207.htm (accessed May 22, 2017).

RELATED STORIES